New drug combo aims to stop leukemia relapse after transplant

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can lower the chance of leukemia returning. It includes 160 people aged 15-60 with high-risk or hard-to-treat acute leukemia or myelodysplastic syndrome. Participants are randomly assigned to receive the new drug combo or standard treatment, then all get a stem cell transplant. The main goal is to see if the new approach reduces relapse within two years.